SCHEMBL7337900

SCHEMBL7337900

N#Cc1ccc2cc(C#CCNC(=O)c3cccc(N)c3)ccc2c1

nearest known ligand 0.45

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
PLAU P00749 3/20 0.45
F2 P00734 1/20 0.45
PLG P00747 1/20 0.45
KLKB1 P03952 1/20 0.45
PRSS1 P07477 1/20 0.45
MCHR1 Q99705 1/20 0.43
GRM5 P41594 3/20 0.42
ALDH1A1 P00352 2/20 0.41
KDM4E B2RXH2 1/20 0.41
KAT6A Q92794 2/20 0.41
GPR139 Q6DWJ6 1/20 0.41
NOS3 P29474 1/20 0.41
NOS1 P29475 1/20 0.41
NOS2 P35228 1/20 0.41
HDAC3 O15379 1/20 0.40
SMPD1 P17405 1/20 0.40
RAB9A P51151 1/20 0.39
GAA P10253 1/20 0.39
NAMPT P43490 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7335568 0.87 NOS3 (0.48) PLAUF2PLGKLKB1PRSS1
Trifluoroacetic Acid SCHEMBL7336945 0.80 ASIC3 (0.46) PLAUF2PLGKLKB1PRSS1
Trifluoroacetic Acid SCHEMBL7336953 0.77 KAT6A (0.36) MCHR1GRM5ALDH1A1KDM4EKAT6A
SCHEMBL31116810 0.71 KDM4E (0.54) ALDH1A1KDM4ERAB9AGAANAMPT
SCHEMBL2150674 0.70 FFAR1 (0.50) ALDH1A1
SCHEMBL5906529 0.69 KDM4E (0.62) ALDH1A1KDM4EGAA
SCHEMBL29944886 0.69 KDM4E (0.62) ALDH1A1KDM4EGAA
SCHEMBL26926680 0.69 GPR139 (0.55) MCHR1GRM5ALDH1A1KAT6AGPR139
SCHEMBL10630944 0.69 ALDH1A1 (0.57) ALDH1A1KDM4EHDAC3RAB9AGAA
SCHEMBL6203164 0.69 GPR139 (0.57) MCHR1GRM5ALDH1A1KAT6AGPR139

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20010049374-A1 Urokinase inhibitors STEELE ANDREW W (US) 2001-12-06 US disclosed
US-6284796-B1 NAPHTHAMIDINE COMPOUNDS ABBOTT LABORATORIES 2001-09-04 US disclosed
US-6258822-B1 ENZYME INHIBITORS OF NAPHTHALENE AMIDINE COMPOUNDS ABBOTT LABORATORIES 2001-07-10 US disclosed
EP-1000018-A2 UROKINASE INHIBITORS Abbott Laboratories (US) 2000-05-17 EP disclosed
WO-1999005096-A2 UROKINASE INHIBITORS ABBOTT LABORATORIES (US) 1999-02-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010049374-A1 Urokinase inhibitors SERPINE1, PLAU, SERPINB1 PLAU 2/4885F2 38/4885PLG 10/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.